Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.

In alpha1-AT deficiency, a misfolded but functionally active mutant alpha1-ATZ (alpha1-ATZ) molecule is retained in the endoplasmic reticulum of liver cells rather than secreted into the blood and body fluids. Emphysema is thought to be caused by the lack of circulating alpha1-AT to inhibit neutrophil elastase in the lung. Liver injury is thought to be caused by the hepatotoxic effects of the retained alpha1-ATZ. In this study, we show that several "chemical chaperones," which have been shown to reverse the cellular mislocalization or misfolding of other mutant plasma membrane, nuclear, and cytoplasmic proteins, mediate increased secretion of alpha1-ATZ. In particular, 4-phenylbutyric acid (PBA) mediated a marked increase in secretion of functionally active alpha1-ATZ in a model cell culture system. Moreover, oral administration of PBA was well tolerated by PiZ mice (transgenic for the human alpha1-ATZ gene) and consistently mediated an increase in blood levels of human alpha1-AT reaching 20-50% of the levels present in PiM mice and normal humans. Because clinical studies have suggested that only partial correction is needed for prevention of both liver and lung injury in alpha1-AT deficiency and PBA has been used safely in humans, it constitutes an excellent candidate for chemoprophylaxis of target organ injury in alpha1-AT deficiency.

[1]  C. Owen,et al.  Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. , 1999, The Journal of clinical investigation.

[2]  D. Lomas,et al.  Heteropolymerization of S, I, and Z α1-antitrypsin and liver cirrhosis , 1999 .

[3]  Satoshi Ishii,et al.  Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.

[4]  A. Verkman,et al.  Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. , 1998, The Journal of clinical investigation.

[5]  D. Lomas,et al.  Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. , 1998, American journal of respiratory cell and molecular biology.

[6]  P. Zeitlin,et al.  A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. , 1998, American journal of respiratory and critical care medicine.

[7]  P. Zeitlin,et al.  In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. , 1997, The Journal of clinical investigation.

[8]  W. Welch,et al.  Correcting temperature-sensitive protein folding defects. , 1997, The Journal of clinical investigation.

[9]  S. Prusiner,et al.  Chemical chaperones interfere with the formation of scrapie prion protein. , 1996, The EMBO journal.

[10]  S. Ōmura,et al.  Degradation of a Mutant Secretory Protein, α1-Antitrypsin Z, in the Endoplasmic Reticulum Requires Proteasome Activity* , 1996, The Journal of Biological Chemistry.

[11]  J. Wine,et al.  Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*) , 1996, The Journal of Biological Chemistry.

[12]  T. Sveger,et al.  Other clinical studyThe liver in adolescents with α1-antitrypsin deficiency☆ , 1995 .

[13]  T. Sveger,et al.  The liver in adolescents with α‐antitrypsin deficiency , 1995 .

[14]  R. Stockley,et al.  The effect of the Z mutation on the ability of alpha 1-antitrypsin to prevent neutrophil mediated tissue damage. , 1994, Biochimica et biophysica acta.

[15]  K. E. Moore,et al.  A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Lomas,et al.  The mechanism of Z α1-antitrypsin accumulation in the liver , 1993, Nature.

[17]  S. Brusilow,et al.  Prospective treatment of urea cycle disorders. , 1991, The Journal of pediatrics.

[18]  S. Brusilow.  Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion , 1991, Pediatric Research.

[19]  R. Crystal,et al.  Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. , 1990, The Journal of clinical investigation.

[20]  D. Alpers,et al.  The alpha 1-antitrypsin gene is expressed in a human intestinal epithelial cell line. , 1989, The Journal of biological chemistry.

[21]  Cliff,et al.  Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. , 1989, The Journal of clinical investigation.

[22]  R. Crystal,et al.  Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. , 1987, The Journal of clinical investigation.

[23]  R. Carrell.  alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. , 1986, The Journal of clinical investigation.

[24]  J. Carlson,et al.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. , 1986, The New England journal of medicine.

[25]  H. Colten,et al.  The cellular defect in alpha 1-proteinase inhibitor (alpha 1-PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. M. George,et al.  Structural and functional characterization of the abnormal Z α1‐antitrypsin isolated from human liver , 1984, FEBS letters.